Cell
cycle inhibitors
include cyclin inhibitors and cyclin-dependent kinases (CDKs), which plays
major role in developing new class of anti-cancer therapies. Also, cell cycle
inhibitors in combination with chemotherapy, overcome drug resistance and
improve cytotoxic efficacy. CDKs are rational targets for cancer treatment,
that could restore cell-cycle checkpoints and may induce apoptosis.
Tolero
Pharmaceuticals, Inc., a clinical-stage company focused on developing novel
therapeutics for hematologic and oncologic disorders, developing alvocidib - a
potent CDK9 inhibitor in combination with cytarabine and daunorubicin. In April
2018, the company presented preclinical data supporting the apoptosis-inducing
activity of alvocidib at the American Association for Cancer Research (AACR)
Annual Meeting in the U.S., Chicago.
Request
to Get the Sample Pages at:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with detailed analysis of
pipeline and clinical trials. Pipeline analysis of drugs by phases includes
product description and development activities including information about
clinical results, designations, collaborations, licencing, grants, technology
and others.
No comments:
Post a Comment